Trial · NCT02845713
Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)
NCT02845713, Phase 1, Completed, University Hospitals Cleveland Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE). Trials, record NCT02845713. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02845713
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)
- NCT number
- NCT02845713
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 66 participants, actual
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Conditions
- Wuchereria Bancrofti Infection
- Interventions
- Ivermectin, Diethylcarbamazine Albendazole (IDA)
- First posted
- 2016-07-27
- Last updated
- 2019-04-26
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Drug Levels | up to 12 hours | Five mil-liters of blood will be taken to test drug levels |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 (aggregate) | up to 1 year | Following drug administration, a review of subjective symptoms will be performed. |
| Secondary | Impact of treatment on Hematuria and Proteinuria | up to 7 days | Urine samples will be collected to examine the the presence and amount of blood and protein in the urine. |
| Secondary | Number worm nests | up to 1 year | In those individuals with LF, an ultrasound examination will be performed to identify the number of adult worm nests both before treatment and after. |
| Secondary | Impact of treatment on Liver Function + | up to 7 days | Blood samples will be collected to examine the impact of treatment on the levels of ALT, AST in the subjects blood. |
| Secondary | Impact of treatment on Hemoglobin Levels | up to 7 days | Blood samples will be collected to examine the impact of treatment on the levels of Hemoglobin in the subjects blood. |
| Secondary | Impact of treatment on White Blood Cells | up to 7 days | Blood samples will be collected to examine the impact of treatment on the levels of white blood count in subjects blood. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers16
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02845713
GET https://conductscience.org/api/trials/v1/NCT02845713/registered